Conservative management of prostate cancer in the prostate specific antigen era: The incidence and time course of subsequent therapy

Journal of Urology

Volumn 166, Issue 5, 2001, Pages 1702-1706

  Zaak, Dirk ^b   Frimberger, Dominic ^b   Stepp, Herbert ^b   Wagner, Simon ^b   Baumgartner, Reinhold ^b   Schneede, Peter ^b   Siebels, Michael ^b   Knüchel, Ruth ^b   Kriegmair, Martin ^b   Hofstetter, Alfons ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms; Survival

Indexed keywords

ANTIANDROGEN; HERBACEOUS AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSERVATIVE TREATMENT; DIET SUPPLEMENTATION; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0034785626     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65657-1     Document Type: Article

References (17)

1. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
2. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer
3. Expectant management and the natural history of localized prostate cancer
4. If you "watch and wait" prostate cancer may progress dramatically
5. Results of conservative management of clinically localized prostate cancer
6. Expectant management of localized prostate cancer
7. Expectant management of clinically localized prostatic cancer
8. Deferred treatment of clinically localized low grade prostate cancer: The experience from a prospective series at the Karolinska Hospital
9. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden
10. Natural history of localized prostatic cancer managed by conservative therapy alone
11. Prospective, conservative management of localized prostate cancer
12. Deferred treatment for prostate cancer
13. Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database. Cancer of the prostate strategic urological research endeavor
14. Duration of pre-clinical prostate cancer based on serial PSA data from the VA normative aging study
15. An analysis of watchful waiting for clinically localized prostate cancer
16. Prostate-Specific antigen (PSA) best practice policy. American Urological Association (AUA)
17. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I: Untreated patients